EU's New CE Certification Rules for AEDs: Impact on Chinese OEM/ODM Manufacturers and Industry Response

Introduction

On March 25, 2026, the EU's Medical Device Regulation (MDR) reclassified Automated External Defibrillators (AEDs) from Class IIa to Class III high-risk medical devices, imposing stricter requirements for clinical evidence, lifecycle reviews by Notified Bodies (NBs), and MDSAP (Medical Device Single Audit Program) compliance. This change directly impacts Chinese OEM/ODM manufacturers, as approximately 67% of China's AED exporters currently fall short of the new standards. The regulation has already triggered urgent revisions to procurement agreements by distributors in Germany and the Netherlands, with potential delivery delays of 4–6 months. The medical device manufacturing and export sectors must closely monitor these developments to mitigate disruptions.

Event Overview

Under the updated MDR, AEDs now require:

• Clinical evaluation data to demonstrate safety and efficacy
• Full lifecycle oversight by EU-designated Notified Bodies
• MDSAP-certified quality management systems

The deadline for compliance is September 2026, affecting all AEDs sold in the EU—including those produced by Chinese OEM/ODM suppliers.

Industries Affected

1. Chinese AED OEM/ODM Manufacturers

Over two-thirds of China's AED exporters lack MDSAP certification and face significant hurdles in compiling clinical evidence. Smaller manufacturers may struggle with the increased costs and technical demands, potentially leading to consolidation in the sector.

2. EU Distributors and Procurement Channels

European importers are revising technical agreements to ensure compliance, with reports of accelerated audits for existing Chinese suppliers. Distributors may shift toward pre-certified manufacturers to avoid supply chain delays.

3. Component and Material Suppliers

Upstream suppliers of AED parts (e.g., batteries, electrodes) must align with enhanced traceability and documentation requirements under Class III standards, impacting procurement timelines.

Key Action Points for Businesses

1. Prioritize MDSAP Certification

Manufacturers should immediately initiate gap analyses against MDSAP requirements, focusing on:
- Design control documentation
- Post-market surveillance systems
- Supplier audit protocols

2. Clinical Data Preparation

For OEMs without existing clinical studies:
- Partner with EU-based clinical research organizations (CROs)
- Leverage existing data from comparable devices under IVDR transitional provisions

3. Engage Notified Bodies Early

Given anticipated bottlenecks in NB reviews, manufacturers are advised to:
- Shortlist NBs with AED expertise (e.g., BSI, TÜV SÜD)
- Submit preliminary documentation for pre-review

4. Supply Chain Contingency Planning

Distributors should:
- Diversify supplier base to include MDSAP-ready manufacturers
- Renegotiate contracts to allocate compliance costs

Industry Observations

Analysis suggests this regulatory shift reflects the EU's emphasis on AED reliability in public-access settings. While challenging, the changes could drive long-term quality improvements for Chinese manufacturers seeking global competitiveness. Notably, the 18-month transition period is shorter than typical medical device reclassification timelines, indicating urgency from EU regulators.

From an industry perspective, the regulation may accelerate two trends:
1. Vertical integration among Chinese OEMs to control clinical data generation
2. Increased M&A activity as smaller players seek partnerships with certified firms

Conclusion

The EU's AED reclassification represents both a compliance challenge and a strategic opportunity for Chinese medical device exporters. While the short-term focus must be on meeting the 2026 deadline, manufacturers should view this as a catalyst for upgrading quality systems to compete in other regulated markets like the U.S. and Japan. The full industry impact will depend on how efficiently Notified Bodies can process the influx of applications in the coming months.

Sources

1. Official EU MDR Amendment (2026)
2. Industry export compliance data from China Medical Device Association (CMDA)
3. Procurement advisory notices from German Medical Technology Association (BVMed)
Ongoing updates expected from EU Commission Q2 2026 implementation guidelines